TECHNOLOGY OF OBTAINING POLYRIBOSYLRIBITOL PHOSPHATE AS AN ACTIVE PHARMACEUTICAL INGREDIENT FOR THE PRODUCTION OF POLYSACCHARIDE VACCINES

Despite the world practice, in the Russian Federation immunization against hemophilic infection is carried out only for the children from risk groups, which may be due to the lack of production of this vaccine in the Russian Federation. Therefore, the development of technology for the preparation of polyribosylribitol phosphate (PRP, the active substance of the Hib vaccine) remains relevant. Earlier, the employees of the federal state unitary enterprise “Saint-Petersburg scientific research institute of vaccines and serums and the enterprise for the production of bacterial preparations” of Federal medical and biologic agency of Russia isolated and identified the strain of Haemophilus influenzae SPB type b B-7884. The conditions for cultivation of the strain B-7884 and primary isolation of PRP from the culture liquid were arranged. The aim of the work was to study the possibility of excluding the centrifugation stage for separating H. influenzae SPB type b B-7884 biomass before clarification on the cascade of filter discs, and the development of subsequent stages of PRP isolation from the obtained intermediate product. Materials and methods. PRP isolation from an inactivated culture liquid of strain B-7884 was carried out by centrifugation, filtration, precipitation, homogenization, extraction under various conditions. The concentration of PRP in the intermediate products was determined by the orcinol method, the identity was determined by the latex agglutination test. Results and discussion. The optimal scheme for isolation and purification of the active pharmaceutical ingredient PRP, including filtration through the cascade of deep filters Zeta plus LP 60 (0.3–0.6 μm) and Zeta plus LP 90 (0.1–0.3 μm), concentration and diafiltration on ultrafiltration cassettes with nominal molecular weight cut-off of 30 kDa, precipitation with 10% cetyltrimethylammonium bromide solution (5% v/v), with subsequent homogenization of the obtained precipitate (in the presence of 12.5% of ethanol from the concentrate volume) and extraction (32.5% ethanol), filtration through depth filters Zeta Plus SP 30 and carbon filters Zeta Plus Carbon R53, and precipitation by 1.0% (v/v) 4.0 M sodium chloride solution and freezing at –(20 ± 2)°C, was developed. Conclusion. The obtained results will become the basis for the further development of the polysaccharide substance and allow us to proceed to the next stage in the development of the vaccine against Haemophilus influenzae type b – conjugation with the carrier protein.

1. World Health Organization: Immunization, Vaccines and Biologicals. Haemophilus influenzae type b (Hib). [In-ternet]. [cited 2018 Jan 29]. Available from: http://www.who.int/immunization/monitoring_surveillance/burden/ vpd/surveillance_type/sentinel/Hib/en/.

2. Yang Y, Pan X, Cheng W, Yang Y, Scherpbier RW, Zhu X, Chen Y, Zhou Y, Jiang Q. Haemophilus influenzae type b carriage and burden of its related diseases in Chinese children: Systematic review and meta-analysis. Vaccine. 2017 Nov 1;35(46):6275–82. DOI: 10.1016/j.vaccine.2017.09.057

3. Wang S, Tafalla M, Hanssens L, Dolhain J. A review of Haemophilus influenzae disease in Europe from 2000-2014: challenges, successes and the contribution of hexavalent combination vaccines. Expert Rev Vaccines. 2017 Nov;16(11):1095–105. DOI: 10.1080/14760584.2017.1383157

4. Chongmelaxme B, Hammanee M, Phooaphirak W, Kotirum S, Hutubessy R, Chaiyakunapruk N. Economic evaluations of Haemophilus influenzae type b (Hib) vaccine: a systematic review. J Med Econ. 2017 Oct;20(10):1094– 106. DOI: 10.1080/13696998.2017.1359181

5. Sakata H, Adachi Y, Morozumi M, Ubukata K. Invasive Haemophilus influenzae infections in children in Kamikawa subprefecture, Hokkaido, Japan, 2006-2015: The effectiveness of H. influenzae type b vaccine. J Infect Chemother. 2017 Jul;23(7):459–62. DOI: 10.1016/j.jiac.2017.03.019

6. Yohou KS, Aka NL, Noufe S, Douba A, Assi Assi B, Dagnan SN. Evaluation of introduction of the Haemophilus influenzae vaccine in Côte d’Ivoire [Article in French]. Sante Publique. 2016 Nov 25;28(5):655–64.

7. Casey RM, Dumolard L, Danovaro-Holliday MC, Gacic-Dobo M, Diallo MS, Hampton LM, Wallace AS. Global Routine Vaccination Coverage, 2015. MMWR Morb Mortal Wkly Rep. 2016 Nov 18;65(45):1270–3. DOI: 10.15585/mmwr.mm6545a5

8. Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebitelej i blagopoluchiya cheloveka [Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing.] МР 3.3.1.0001-10 Epidemiologiya i vakcinoprofilaktika gemofil’noj infekcii tipa b [Epidemiology and vaccine prophylaxis for hemophilic infection of type b]. Moscow, 2010. 32 p. Russian.

9. Soyuz pediatrov Rossii [Union of pediatricians of Russia]. Federal’nye klinicheskie rekomendacii po vakcinoprofilaktike gemofil’noj infekcii tipa b u detej [Federal clinical recommendations for the vaccination of Haemophilic type-b infection in children]. [Internet]. [cited 2018 Jan 29]. Available from: http://www.pediatr-russia.ru/sites/ default/files/file/kr_gemib.pdf. Russian.

10. Prikaz Minzdrava Rossii ot 21.03.2014 № 125n «Ob utverzhdenii nacional’nogo kalendarya profilakticheskih privivok i kalendarya profilakticheskih privivok po ehpidemicheskim pokazaniyam» [Order of the Ministry of health of the Russian Federation of March 21, 2014 No. 125n “On the approval of the national calendar of preventive vaccinations and the calendar of preventive vaccinations for epidemic indications”]. Russian.

11. Salimova EL, Konon AD, Truhin VP, Petrovskii SV, Krasilnikov IV. Haemophilus influenzae SPB tip b V-7884 – proizvodstvennyj shtamm polisaharidnyh vakcin [Haemophilus influenzae SPB type b V-7884 – master seed strain of polysaccharide vaccines]. Actual biotechnology. 2016;3(18):77–81. Russian.

12. Trukhin VP, Petrovskii SV, Krasilnikov IV, Nacharova EP, Yevtushenko AE, Salimova EL, Konon AD, Ujba SV. inventor; Shtamm Haemophilus influenzae SPB tip b – vysokoaktivnyj producent kapsul’nogo polisaharida poliribozilribitolfosfata [The Haemophilus influenzae SPB type b strain is a highly active producer of the capsular polysaccharide polyribosyl ribitol phosphate]. Russian Federation RU 2624014. 2017 Jun 30. Russian.

13. Konon AD, Salimova EL, Truhin VP, Petrovskii SV, Krasilnikov IV. Osobennosti kul’tivirovaniya Haemophilus influenzae SPB tip b V-7884 – producenta poliribozilribitolfosfata [Features of Haemophilus influenzae SPB type b B-7884 cultivation – a producer of polyribosylribitol phosphate]. Actual biotechnology. 2016;3(18):67–71. Russian.

14. Salimova EL, Konon AD, Basakina II, Krasilnikov IV. Vydelenie celevogo produkta polisaharida poliribozilribitolfosfata iz kul’tural’noj zhidkosti Haemophilus influenzae tip b s cel’yu proizvodstva substancii dlya polisaharidnyh vakcin [Isolation of the target product polyribosylribitol phosphate polysaccharide from a culture liquid of Haemophilus influenzae type b to produce a substance for polysaccharide vaccines]. V Vserossijskaya nauch-no-prakticheskaya konferenciya s mezhdunarodnym uchastiem «Innovacii v zdorov’e nacii» (St. Petersburg, No-vember 8-9, 2017). P. 337–340. Russian.

15. Konon AD, Salimova EL, Basakina II, Krasilnikov IV. Optimizaciya metodiki opredeleniya koncentracii poliribozilribitolfosfata v processe proizvodstva substancii dlya polisaharidnyh vakcin [Optimization of the method for determining the concentration of polyribosylribitol phosphate in the production of a substance for polysaccharide vaccines]. V Vserossijskaya nauchno-prakticheskaya konferenciya s mezhdunarodnym uchastiem «Innovacii v zdorov’e nacii» (St. Petersburg, November 8–9, 2017). P. 194–198. Russian.

16. Junqiang L, Qian S, Qiumin Zh, Yabing L, Hejun L, Yongjie J, inventor; Tasly Pharmaceutical Group Co., Ltd., assignee. Haemophilus influenzae type B polysaccharide conjugate vaccine preparation method. CN103623404 (B). 2016 Aug 03.

17. Acep R, Neni N. Isolation and purification of capsular polysaccharide of Haemophilus influenzae type b (Hib) by hexadecyltrimethylammonium bromide (CTAB) precipitation and chromatography. Proceeding of The International Seminar on Chemistry. 2008 Oct: 294–6.

18. Hamidi A, Beurret MF, inventor; De Staat Der Nederlanden, Vert. Door De Minister Van Vws, assignee. Process for producing a capsular polysaccharide for use in conjugate vaccines. United States patent. US 7582459 B2. 2009 Sep 1.

19. Ella KM, Ramasamy V, Naidu MG, Sarma AD, inventor; Bharat Biotech International Limited, assignee. Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof. World intellectual property organization WO 2014009971 (A2). 2014 Jan 16.

20. Wieruszeski JM, Talaga P, Lippens G. Development of a high-resolution magic-angle spinning nuclear magnetic resonance identity assay of the capsular polysaccharide from Haemophilus influenzae type b present in cetavlon precipitate. Anal Biochem. 2005 Mar 1;338(1):20–5. DOI: 10.1016/j.ab.2004.10.038

21. Biswas SC, Chattoraj DK. Polysaccharide-surfactant interaction. 2. Bindingof cationic surfactants to car-boxymethyl cellulose and dextrin. Langmuir. 1997;13:4512–9.

22. Bao H, Li L, Gan LH, Zhang H. Interactions between ionic surfactants and polysaccharides in aqueous solutions. Macromolecules. 2008;41(23):9406–12.

23. Maulik S, Jana P, Moulik S, Chattoraj D. Biopolymer-surfactant interation. I. Kinetics of binding of cetyltrimethyl ammonium bromide with carboxymethylcellulose. Biopolymers. 1995;35:533–41. DOI: 10.1002/bip.360350512

24. Noyes A, Boesch A, Godavarti R, Titchener-Hooker N, Coffman J, Mukhopadhyay T. High throughput quantifi-cation of capsular polysaccharides for multivalent vaccines using precipitation with a cationic surfactant. Vaccine. 2013 Nov 19;31(48):5659–65. DOI: 10.1016/j.vaccine.2013.09.075

25. Rana R, Dalal J, Singh D, Kumar N, Hanif S, Joshi N, Chhikara MK .Development and characterization of Haemophilus influenzae type b conjugate vaccine prepared using different polysaccharide chain lengths. Vaccine. 2015 May 28;33(23):2646–54. DOI: 10.1016/j.vaccine.2015.04.031

26. Abdelhameed AS, Adams GG, Morris GA, Almutairi FM, Duvivier P, Conrath K, Harding SE. A glycoconjugate of Haemophilus influenzae Type b capsular polysaccharide with tetanus toxoid protein: hydrodynamic properties mainly influenced by the carbohydrate. Sci Rep. 2016 Feb 26;6:22208. DOI: 10.1038/srep22208

27. Sigma Aldrich: Glycobiology Analysis Manual, 2nd Edition. Lipopolysaccharides. [Internet]. [cited 2018 Jan 29]. Available from: https://www.sigmaaldrich.com/content/dam/sigma-aldrich/articles/biology/Glycobiology/glyco-biology-pdf/lipopolysaccharides.pdf.

28. Arsang A, Tabatabaie A, Vaziri F, Nejati M, Zolfaghari MR, Fateh A, Jamnani FR, Bahrmand AR, Siadat SD. Optimization of large scale production of Haemophilus influenzae type b polyribosyl-ribitol phosphate. Minerva Biotecnologica. 2017 March;29(1):17–23. DOI: 10.23736/S1120-4826.16.01855-3